The Japanese hypertension guideline was first published in 2000, and it has been revised every 4 or 5 years. Currently, we are revising the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH) 2014 3 and will publish a new guideline in April 2019. In this article, we summarize the key points of the JSH2019 and discuss the differences between these 3 guidelines.
Epidemiology of Hypertension in Japan
In Japan, 43 million people are hypertensive, of which only 50% are treated, and about 25% are controlled at the target blood pressure (BP) level of <140/90 mm Hg. Because of the large number of hypertensive population and poor control rate, hypertension is one of the leading causes of death (next to smoking) in Japan.
The average systolic BP decreases markedly over the past 50 years. The age-adjusted mortality owing to stroke reached a peak in the 1960s and then rapidly decreased. The decrease in stroke mortality as the result of improved hypertension management may have contributed significantly to longevity of Japanese. However, the biggest problem is the gap between average life expectancy and healthy life expectancy. In men, average life expectancy increased from 78.1 years in 2001 to 81.0 years in 2016, whereas healthy life expectancy increased from 69.4 to 72.4 years. During the same period, women's average life expectancy and healthy life expectancy increased from 85.0 to 87.1 years and from 72.7 to 74.8 years, respectively. Thus, the gaps between average and healthy life expectancies have remained to be about 8 years in men and 12 years in women. These situations have resulted in an increased number of elderly people who need nursing care. About 45% of the causes for requirement of nursing care are related to hypertension (stroke, heart failure, and cognitive dysfunction). Taking this serious situation into consideration, Japanese government promulgated the Fundamental Law for the Act on Measures for Cardiovascular Disease to extend healthy life expectancy in December 2018.
Classification of BP Levels and Definition of Hypertension
In the 2017ACC/AHA hypertension guidelines, 1 130/80 mm Hg or higher is adopted as the hypertension definition. In addition, the prehypertension category in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure has been replaced with the term elevated BP to convey the message of increased cardiovascular disease (CVD) risk compared with normal BP (<120/80 mm Hg). In contrast, the 2018 ESC/ESH guideline maintains the diagnostic threshold of hypertension at 140/90 mm Hg. 2 We have extensively discussed these issues from various viewpoints (epidemiological and interventional evidence, influences on public), and we will not change the definition of hypertension but change the term of BP classification (Table 1 ). We will replace optimal in JSH2014 with normal to convey the message that BP above 120/80 mm Hg is not normal, and is associated with increased CVD risk from the epidemiological point of view. The terms normal BP and high normal BP in JSH2014 will be replaced with high normal BP and elevated BP, respectively. The introduction of the term of elevated BP reflects concept that BP of this category is high enough to be managed (mostly through lifestyle modification) to prevent CVD in the general population.
We will not change the definition or category of hypertension because we think it appropriate to define hypertension as the level of BP at which the benefits of treatment unequivocally outweigh the risks of treatment in line with the ESC/ ESH guideline.
BP Monitoring Outside of the Office and Management of Hypertension
The ACC/AHA guideline recommends out of office BP measurements for confirming the diagnosis of hypertension and for titration of BP-lowering medication with Class I and level
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Correspondence The prevalence of cardiovascular disease in Japan is known to be lower than that of other developed countries. However, the prevalence and mortality rate of cerebrovascular disease is higher than in United States and Europe. Because stroke and heart failure have stronger association with higher BP than coronary artery disease, lowering the BP goal to systolic BP/ diastolic BP <130/80 mm Hg would be suitable for Japanese hypertensive patients. To achieve this BP goal, comprehensive approaches including lifestyle modification are extremely important. Because both hypertension treatment and control rates are low in young and middle-age hypertensive patients, targeting these populations through high risk and population strategies is extremely important, but it remains to be a big challenge in Japan.
Initiation of Drug Treatment and Lifestyle Modification
The ACC/AHA guideline adopted the 10-year risk of atherosclerotic CVD to determine whether drug treatment should be initiated in patients with BP of 130 to 139/80 to 89 mm Hg.
In the JSH2019, risk factors and risk stages will also be determined according to the Hisayama score 6 and the JALS (Japan Arteriosclerosis Longitudinal Study) score 7 for the 10-year CVD risk.
Guidelines emphasize that lifestyle modification is an essential component for BP management, and they recommend promoting optimal lifestyle habits throughout life. JSH2019 will also recommend maintaining/promoting appropriate lifestyle habits even in normotensive people. However, salt intake is high, and the prevalence of obesity and metabolic syndrome is increasing in Japan. In a recent survey of patients with hypertension recruited from general practitioner-based clinics, the average salt intake was 10.2 g/day, and the prevalence of salt intake of <6 g/day was only 6.7%. 8 In addition, the impact of obesity on BP seems to be greater in Japanese than that in the US population.
Structured Team-Based Care and Overcoming Clinical Inertia
Hypertension often has no symptom. Therefore, detection, diagnosis, and treatment of hypertension are still major challenges. Particularly, the failure to adopt healthy lifestyles has been a critical factor in hypertension management in Japan, and it must be addressed urgently. To achieve proper control of BP, patient-centered and structured team-based care is extremely important as shown in ACC/ AHA. In addition, clinical inertia contributes significantly to low control rate of hypertension. To overcome the problem of clinical inertia, various programs should be formed by all stakeholders, including local residents, policy makers, health-care professionals, industries, and academic and professional societies.
Conclusion and Perspective
Although the definition of hypertension will not be changed, more strict BP control will be recommended in JSH2019. These changes are in line with ACC/AHA and ESC/ESH guidelines. To reduce noncommunicable diseases, the Japanese government has recently introduced several nationwide programs, such as specific health checkups and specific health guidance and severe illness prevention. It is expected that these political measures would help improving hypertension management and extending healthy life expectancy.
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